Menu Search
Equities

Inhibikase Therapeutics Inc

IKT:NAQ

Inhibikase Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.01
  • Today's Change0.03 / 1.52%
  • Shares traded257.16k
  • 1 Year change+113.83%
  • Beta1.0461
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Inhibikase Therapeutics Inc had net income fall 5.40% from a loss of 18.05m to a larger loss of 19.03m despite a 111.03% increase in revenues from 123.44k to 260.50k.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-175.81%
Return on equity-270.10%
Return on investment-267.87%
More ▼

Cash flow in USDView more

In 2023, Inhibikase Therapeutics Inc increased its cash reserves by 27.50%, or 1.98m. Cash Flow from Investing totalled 11.66m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 18.09m for operations while cash generated from financing totalled 8.41m.
Cash flow per share-2.70
Price/Cash flow per share--
Book value per share-0.0711
Tangible book value per share-0.0711
More ▼

Balance sheet in USDView more

Inhibikase Therapeutics Inc has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 9.17m.
Current ratio0.8538
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.